B7-2 Antibody (BU63): sc-19617

B7-2 Antibody (BU63) is a mouse monoclonal IgG1 kappa light chain antibody that detects B7-2 protein in resting monocytes and dendritic cells, as well as activated T, B, and natural killer cells from mouse, rat, and human sources through western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and flow cytometry (FCM). Anti-B7-2 antibody (BU63) is offered in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. B7-2 protein, also known as CD86, plays a crucial role in the immune response by providing essential costimulatory signals necessary for T cell activation. B7-2 (BU63) monoclonal antibody interacts with T cell receptors CD28 and CTLA-4, which are vital for T cell proliferation and lymphokine production. B7-2 binding to CD28 enhances T cell activation, while B7-2 interaction with CTLA-4 serves as a negative regulatory signal, thus maintaining immune homeostasis. This dual functionality underscores B7-2′s importance in modulating immune responses, making B7-2 a significant target for therapeutic interventions in various diseases, including cancer and autoimmune disorders. B7-2 (BU63) antibody is an invaluable tool for researchers studying T cell activation and the intricate balance of immune signaling pathways.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

B7-2 Antibody (BU63) References:

1. B7-2 expression on tumor cells is important for the acquisition of cytotoxic T lymphocyte activity by spleen cells from low-dose-melphalan-treated MOPC-315 tumor bearers via a mechanism that requires either B7-1 or B7-2 expression on host antigen-presenting cells.  |  Sojka, DK., et al. 2000. Cancer Immunol Immunother. 49: 10-22. PMID: 10782862
2. B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse.  |  Pentcheva-Hoang, T., et al. 2004. Immunity. 21: 401-13. PMID: 15357951
3. Functional B7.2 and B7-H2 molecules on myeloma cells are associated with a growth advantage.  |  Yamashita, T., et al. 2009. Clin Cancer Res. 15: 770-7. PMID: 19188146
4. Lack of B7-1 and B7-2 costimulatory molecules modulates the severity of group B Streptococcus-induced arthritis.  |  Puliti, M., et al. 2010. Microbes Infect. 12: 302-8. PMID: 20114085
5. Triple expression of B7-1, B7-2 and 4-1BBL enhanced antitumor immune response against mouse H22 hepatocellular carcinoma.  |  Li, G., et al. 2011. J Cancer Res Clin Oncol. 137: 695-703. PMID: 20563597
6. Cryptic association of B7-2 molecules and its implication for clustering.  |  Lankipalli, S., et al. 2021. Protein Sci. 30: 1958-1973. PMID: 34191384
7. A T cell lymphoma can provide potent co-stimulatory effects to T cells that are not mediated by B7-1, B7-2, CD40, HSA or CD70.  |  Nieland, JD. and Kruisbeek, AM. 1995. Int Immunol. 7: 1827-38. PMID: 8580081
8. Rejection of MHC class II-transfected tumor cells requires induction of tumor-encoded B7-1 and/or B7-2 costimulatory molecules.  |  Baskar, S., et al. 1996. J Immunol. 156: 3821-7. PMID: 8621919
9. Effects of blocking B7-1 and B7-2 interactions during a type 2 in vivo immune response.  |  Greenwald, RJ., et al. 1997. J Immunol. 158: 4088-96. PMID: 9126967
10. B7-1 or B7-2 is required to produce the lymphoproliferative phenotype in mice lacking cytotoxic T lymphocyte-associated antigen 4 (CTLA-4).  |  Mandelbrot, DA., et al. 1999. J Exp Med. 189: 435-40. PMID: 9892625

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-B7-2 Antibody (BU63) has 18 citations in a variety of scientific publications.

Primary antibodies like Anti-B7-2 Antibody (BU63) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

B7-2 Antibody (BU63) Specifications

Alternate Product Name: B7-2

Product Clone Name: BU63

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids:

Epitope Target: B7-2

Epitope Species: human

Product Reactivity/Detection: B7-2 of resting monocytes and dendritic cells, and activated T, B and natural killer cells

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, FCM

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 18 citations in various scientific publications

Available Conjugates/Forms for B7-2 Antibody (BU63): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin

The preferred B7-2 antibody is B7-2 Antibody (D-6): sc-28347.